Finerenone in IgA nephropathy: real-world 12-month propensity-matched cohort demonstrating proteinuria reduction, eGFR preservation, and safety profile

Objective To evaluate the efficacy and safety of finerenone in patients with IgA nephropathy (IgAN).Methods This retrospective study included 105 patients with IgAN (35 in the finerenone group, 70 in the control group) from January 2022 to February 2025. The finerenone group received conventional th...

Повний опис

Бібліографічні деталі

Автори:	Wei Zhang, Jing-ting Yu, Bo Lin, Xiaogang Shen, Maosheng Chen, Yi-dong Zhou, Yu-jia Zhang, Cheng-cong Zhuo, Zhi-liang Jiang, Bin Zhu
Формат:	Artigo
Мова:	Inglês
Опубліковано:	Taylor & Francis Group 2026-12-01
Серія:	Renal Failure
Предмети:	IgA nephropathy finerenone non-steroidal mineralocorticoid receptor antagonist (MRA) proteinuria eGFR decline real-world evidence
Онлайн доступ:	https://www.tandfonline.com/doi/10.1080/0886022X.2026.2644719
Теги:	Додати тег Немає тегів, Будьте першим, хто поставить тег для цього запису!